

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY DOCKET NO.
217408US0CONTSERIAL NO.
10/022,874


LIST OF REFERENCES CITED BY APPLICANT

APPLICANT
Chika NAKANISHI et al



MAY 24 2005

FILING DATE
December 20, 2001GROUP
1625




U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	4,616,002	10/07/86	Bruno KAMBER et al			
	AB	5,767,131	06/16/98	Charles GLUCHOWSKI et al			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						




FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
	AO	WO 99/43658	09/02/99	WIPO	1	
	AP	0 520 200	12/30/92	EPO		
	AQ	08-041052	02/13/96	JAPAN (w/attached English abstract)		XXX
	AR	0 622 364	11/02/94	EPO		
	AS	WO 94/22829	10/13/94	WIPO		
	AT	62-175462	08/01/87	JAPAN		XXX
	AU					
	AV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	Brian COX et al, <i>Exp. Opin. Ther. Patents</i> , "N-type calcium channel blockers in pain and stroke", 1998, 8(10), pp. 1237-1250.	
	AX	Peter R. DODD et al, <i>Neurochem. Int.</i> , "Excitotoxic Mechanisms in The Pathogenesis of Dementia", 1994, Vol. 25, No. 3, pp. 203-219.	
	AY	Klaus W. LANGE et al, <i>Neuroscience and Biobehavioral Reviews</i> , "Dopamine/Glutamate Interactions in Parkinson's Disease", 1997, Vol. 21, No. 4, pp. 393-400.	
	AZ	Karl D. KIEBURTZ et al, <i>Arch. Neurol.</i> , "Excitotoxicity and Dopaminergic Dysfunction in the Acquired Immunodeficiency Syndrome Dementia Complex", December 1991, Vol. 48, pp. 1281-1284.	<input checked="" type="checkbox"/> Additional References sheet(s) attached
Examiner 			Date Considered 8/1/05

*Examiner Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 217408US0CONT		SERIAL NO. 10/022,874	
LIST OF REFERENCES CITED BY APPLICANT 				APPLICANT Chika NAKANISHI et al			
				FILING DATE December 20, 2001		GROUP 1625	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AAA	Toshio IMAIZUMI et al, Brain Research, "The role of voltage-gated Ca ²⁺ channels in anoxic injury of spinal cord white matter", 1999, Vol. 817, pp. 84-92.					
	AAB	Ken P. MADDEN et al, Brain Research, "Treatment with conotoxin, an 'N-type' calcium channel blocker, in neuronal hypoxic-ischemic injury", Vol. 537, 1990, pp. 256-262.					
	AAC	D. M. WHITE et al, Brain Research, "Effect of subcutaneous administration of calcium channel blockers on nerve injury-induced hyperalgesia", 1998, Vol. 801, pp. 50-58.					
	AAD	Laura BASILICO et al, European Journal of Pharmacology, "Influence of ω -conotoxin on morphine analgesia and withdrawal syndrome in rats", 1992, Vol. 218, pp. 75-81.					
	AAE	R. C. PIERCE et al, The Journal of Pharmacology Experimental Therapeutics, "Calcium-Mediated Second Messengers Modulate the Expression of Behavioral Sensitization to Cocaine", 1998, Vol. 286, No. 3, pp. 1171-1176.					
	AAF	Kazuyuki MURASE et al, Brain Research, "Serotonin suppresses N-methyl-D-aspartate responses in acutely isolated spinal dorsal horn neurons of the rat", Vol. 525, 1990, pp. 84-91.					
	AAG	Dhanapalan NAGARATHNAM et al, J. Med. Chem., "Design and Synthesis of Novel σ_{1a} Adrenoceptor-Selective Dihydropyridine Antagonists for the Treatment of Benign Prostatic Hyperplasia", Vol. 41, 1998, pp. 5320-5333.					
	AAH	Wai C. WONG et al, J. Med. Chem., "Identification of a Dihydropyridine as a Potent σ_{1a} Adrenoceptor Selective Antagonist That Inhibits Phenylephrine-Induced Contraction of the Human Prostate", Vol. 41, 1998, pp. 2643-2650.					
	AAI	J. B. SAINANI et al, Indian Journal of Chemistry, "Formation of 1,4,5,6,7,8-hexahydro-pyrido[4,3-b]pyridine by Hantzsch synthesis", Vol. 34B, January 1995, pp. 17-20.					
	AAJ						
	AAK						
	AAL						
	AAM						
	AAN						
	AAO						
	AAP						
	AAQ						
Examiner 					Date Considered 8/1/05		
*Examiner Initial If reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							